Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for advanced gastric cancer (JCOG1013, GC_CS/DCS_P3 ADOPT)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms ADOPT
- 05 Jun 2018 Primary endpoint (Overall survival) has not been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results (n=741) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 30 Mar 2016 Status changed from recruiting to active, no longer recruiting.